Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $46.70, for a total value of $7,763,875.00. Following the completion of the sale, the chief executive officer directly owned 8,808,533 shares in the company, valued at approximately $411,358,491.10. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 1.6%

Shares of NASDAQ:TEM opened at $50.47 on Friday. The company has a market cap of $9.06 billion, a P/E ratio of -29.34 and a beta of 3.99. The stock’s 50-day moving average is $48.73 and its 200-day moving average is $58.19. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s revenue was up 36.1% compared to the same quarter last year. During the same period last year, the business posted ($0.24) earnings per share. Equities research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

TEM has been the topic of a number of recent research reports. Guggenheim decreased their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research report on Wednesday, February 25th. Morgan Stanley decreased their target price on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Jefferies Financial Group initiated coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their target price on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $68.64.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently made changes to their positions in the business. JPL Wealth Management LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI during the third quarter valued at approximately $38,000. Whittier Trust Co. boosted its holdings in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares in the last quarter. Finally, Lodestone Wealth Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.